Comparison of Different Antibiotic Regimes for Preventive Tooth Extractions in Patients with Antiresorptive Intake-A Retrospective Cohort Study

Overview

Journal Antibiotics (Basel)

Specialty Pharmacology

Date 2023 Jun 28

PMID 37370316

Authors

Oliver Ristow

Thomas Ruckschloss

Gregor Schnug

Julius Moratin

Moritz Bleymehl

Sven Zittel

Maximilian Pilz

Caroline Sekundo

Christian Mertens

Michael Engel

Jurgen Hoffmann

Maximilian Smielowski

Affiliations

Soon will be listed here.

Abstract

In the present study, the impacts on success rates between three different antibiotic regimes in patients receiving preventive tooth extraction during/after antiresorptive treatment were compared. For the retrospective analysis, we enrolled patients who had undergone tooth extraction from 2009 to 2019 according to the specified preventive conditions under antiresorptive therapy. Three antibiotic regimens were distinguished: (Group 1) intravenous for 7 days, (Group 2) oral for 14 days, and (Group 3) oral for 7 days of application. The primary endpoint was the occurrence of medication-related osteonecrosis of the jaw at 12 weeks after surgery. A total of 760 patients and 1143 extraction regions were evaluated (Group 1 = 719; Group 2 = 126; Group 3 = 298). The primary endpoint showed no significant difference in the development of medication-related osteonecrosis of the jaw between the groups studied (Group 1 = 50/669 (7%); Group 2 = 9/117 (7%); Group 3 = 17/281 (6%); = 0.746). Overall, the success rate was 93% after intervention when preventive measures were followed. With the same success rate, a reduced, oral administration of antibiotics seems to be sufficient regarding the possible spectrum of side effects, the development of resistance and the health economic point of view.

Citing Articles

Ruan H, Li M, Zhang Z, Ma H, He Y Clin Oral Investig. 2024; 28(10):549.

PMID: 39317736 PMC: 11422288. DOI: 10.1007/s00784-024-05911-z.

References

Beth-Tasdogan N, Mayer B, Hussein H, Zolk O, Peter J . Interventions for managing medication-related osteonecrosis of the jaw. Cochrane Database Syst Rev. 2022; 7:CD012432. PMC: 9309005. DOI: 10.1002/14651858.CD012432.pub3. View

Debieve M, Castiaux L, van Maanen A, Magremanne M . Medication-related osteonecrosis of the jaw, a risk to reassess in osteoporotic patients. J Stomatol Oral Maxillofac Surg. 2022; 124(1S):101316. DOI: 10.1016/j.jormas.2022.10.015. View

Avishai G, Muchnik D, Masri D, Zlotogorski-Hurvitz A, Chaushu L . Minimizing MRONJ after Tooth Extraction in Cancer Patients Receiving Bone-Modifying Agents. J Clin Med. 2022; 11(7). PMC: 8999581. DOI: 10.3390/jcm11071807. View

Milic T, Raidoo P, Gebauer D . Antibiotic prophylaxis in oral and maxillofacial surgery: a systematic review. Br J Oral Maxillofac Surg. 2021; 59(6):633-642. DOI: 10.1016/j.bjoms.2020.09.020. View

Fedele S, Bedogni G, Scoletta M, Favia G, Colella G, Agrillo A . Up to a quarter of patients with osteonecrosis of the jaw associated with antiresorptive agents remain undiagnosed. Br J Oral Maxillofac Surg. 2014; 53(1):13-7. DOI: 10.1016/j.bjoms.2014.09.001. View

Schwech N, Nilsson J, Gabre P . Incidence and risk factors for medication-related osteonecrosis after tooth extraction in cancer patients-A systematic review. Clin Exp Dent Res. 2022; 9(1):55-65. PMC: 9932256. DOI: 10.1002/cre2.698. View

Hasegawa T, Kawakita A, Ueda N, Funahara R, Tachibana A, Kobayashi M . A multicenter retrospective study of the risk factors associated with medication-related osteonecrosis of the jaw after tooth extraction in patients receiving oral bisphosphonate therapy: can primary wound closure and a drug holiday really prevent.... Osteoporos Int. 2017; 28(8):2465-2473. DOI: 10.1007/s00198-017-4063-7. View

Zirk M, Wenzel C, Buller J, Zoller J, Zinser M, Peters F . Microbial diversity in infections of patients with medication-related osteonecrosis of the jaw. Clin Oral Investig. 2018; 23(5):2143-2151. DOI: 10.1007/s00784-018-2655-z. View

Poxleitner P, Ermer M, Trittler R, Feuerstein C, Otten J, Schmelzeisen R . Concentration of Penicillin G in Jawbone Affected by Antiresorptive Agent-Related Osteonecrosis Following a Single Preoperative Dose. Antibiotics (Basel). 2020; 10(1). PMC: 7824264. DOI: 10.3390/antibiotics10010017. View

10.

Ueda N, Nakashima C, Aoki K, Shimotsuji H, Nakaue K, Yoshioka H . Does inflammatory dental disease affect the development of medication-related osteonecrosis of the jaw in patients using high-dose bone-modifying agents?. Clin Oral Investig. 2020; 25(5):3087-3093. DOI: 10.1007/s00784-020-03632-7. View

11.

Cabras M, Gambino A, Broccoletti R, Sciascia S, Arduino P . Lack of evidence in reducing risk of MRONJ after teeth extractions with systemic antibiotics. J Oral Sci. 2021; 63(3):217-226. DOI: 10.2334/josnusd.21-0016. View

12.

Otto S, Troltzsch M, Jambrovic V, Panya S, Probst F, Ristow O . Tooth extraction in patients receiving oral or intravenous bisphosphonate administration: A trigger for BRONJ development?. J Craniomaxillofac Surg. 2015; 43(6):847-54. DOI: 10.1016/j.jcms.2015.03.039. View

13.

Matsumoto A, Sasaki M, Schmelzeisen R, Oyama Y, Mori Y, Voss P . Primary wound closure after tooth extraction for prevention of medication-related osteonecrosis of the jaw in patients under denosumab. Clin Oral Investig. 2016; 21(1):127-134. DOI: 10.1007/s00784-016-1762-y. View

14.

Fusco V, Campisi G, Bedogni A . One changing and challenging scenario: the treatment of cancer patients with bone metastases by bisphosphonates and denosumab, the cost-benefit evaluation of different options, and the risk of medication-related osteonecrosis of the jaw (MRONJ). Support Care Cancer. 2022; 30(9):7047-7051. PMC: 8935879. DOI: 10.1007/s00520-022-06982-y. View

15.

Bodem J, Kargus S, Eckstein S, Saure D, Engel M, Hoffmann J . Incidence of bisphosphonate-related osteonecrosis of the jaw in high-risk patients undergoing surgical tooth extraction. J Craniomaxillofac Surg. 2015; 43(4):510-4. DOI: 10.1016/j.jcms.2015.02.018. View

16.

. . Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2018; 61(4):448-473. DOI: 10.1007/s00103-018-2706-2. View

17.

Mauceri R, Coniglio R, Abbinante A, Carcieri P, Tomassi D, Panzarella V . The preventive care of medication-related osteonecrosis of the jaw (MRONJ): a position paper by Italian experts for dental hygienists. Support Care Cancer. 2022; 30(8):6429-6440. PMC: 9213300. DOI: 10.1007/s00520-022-06940-8. View

18.

Schiodt M, Otto S, Fedele S, Bedogni A, Nicolatou-Galitis O, Guggenberger R . Workshop of European task force on medication-related osteonecrosis of the jaw-Current challenges. Oral Dis. 2019; 25(7):1815-1821. DOI: 10.1111/odi.13160. View

19.

Soutome S, Otsuru M, Hayashida S, Murata M, Yanamoto S, Sawada S . Relationship between tooth extraction and development of medication-related osteonecrosis of the jaw in cancer patients. Sci Rep. 2021; 11(1):17226. PMC: 8390686. DOI: 10.1038/s41598-021-96480-8. View

20.

Fusco V, Rossi M, Fasciolo A, Gambino A, Palmeri S . Prognosis of metastatic bone cancer and myeloma patients and long-term risk of medication-related osteonecrosis of the jaw (MRONJ): some critical points. Support Care Cancer. 2022; 30(12):9707-9709. DOI: 10.1007/s00520-022-07214-z. View